Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16101987 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL16119412 | 0.94 | HTT (0.32) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL16100774 | 0.94 | HTT (0.32) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL16100777 | 0.94 | HTT (0.32) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL16101638 | 0.94 | HTT (0.32) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL16119410 | 0.94 | HTT (0.32) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL16100710 | 0.91 | ALDH1A1 (0.35) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL17465696 | 0.91 | ALDH1A1 (0.35) | ALDH1A1HTTRECQLNPSR1KDM4E | |
| SCHEMBL16100945 | 0.90 | MEN1 (0.35) | ALDH1A1HTTKDM4EGAA | |
| SCHEMBL17465675 | 0.90 | DRD4 (0.35) | ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
| WO-2014151958-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | ALDH1A1 305/4885HTT 4789/4885RECQL 1519/4885 |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ALDH1A1 305/4885HTT 4789/4885RECQL 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.